In a landscape where medical technology is evolving at an unprecedented pace, the American Society of Plastic Surgeons (ASPS) has reaffirmed its commitment to the future of the specialty. The organization has officially unveiled the five innovative startups selected for the 2026 MedTech Innovator (MTI) Plastic Surgery track—a prestigious accelerator program designed to bridge the gap between groundbreaking medical research and clinical application.
As the intersection of digital health, advanced diagnostics, and surgical instrumentation becomes increasingly vital to patient outcomes, this collaboration serves as a critical incubator for the next generation of plastic surgery solutions.
The 2026 Cohort: A New Wave of Surgical Innovation
The five startups selected to represent the ASPS track—FeminAI, ImageAssist, GenesisTissue, Tissuelock, and GenAssist—were chosen from a highly competitive pool of 135 applicants. Each firm brings a unique technological focus, ranging from artificial intelligence in surgical planning to bio-engineered tissue solutions.
These companies are now part of a broader cohort of 65 startups vying for a share of $800,000 in non-dilutive funding. The winners of the overall program are slated to be announced this fall at The MedTech Conference in Boston, an event that serves as the global nexus for medical device and digital health development.
The selection process was rigorous, involving a multi-stage review that culminated in a live-pitch event in San Francisco. There, 12 finalists presented their technologies before a panel of judges comprised of leading plastic surgeons, venture capitalists, and industry experts. The resulting top five represent the most promising ventures that align with the clinical needs of surgeons and the long-term well-being of patients.
Chronology of the Partnership: Five Years of Progress
The collaboration between the ASPS and MedTech Innovator is now in its fifth year, a milestone that underscores the sustained success of this strategic partnership.
The Evolution of the Track
- 2021–2022: Establishing the Foundation. The partnership began as a pilot initiative to integrate plastic surgery expertise into the broader MedTech Innovator framework. Early results demonstrated that plastic surgeons could provide unique, high-value feedback that traditional medtech accelerators often lacked.
- 2023: Scaling Impact. As the track gained traction, application numbers surged. The program began to see an uptick in interest from digital health startups, particularly those focused on pre-operative imaging and post-operative monitoring.
- 2024–2025: Maturation. The program transitioned from a purely educational initiative into a commercialization engine. During this period, participant startups began securing significant Series A and B funding rounds.
- 2026: The Current Cohort. With 135 applicants, the interest in the Plastic Surgery track has reached an all-time high, cementing the ASPS’s role as a primary gateway for medtech firms looking to enter the reconstructive and aesthetic markets.
Supporting Data: By the Numbers
The impact of the ASPS/MTI collaboration is reflected in robust quantitative data that highlights the efficacy of the accelerator model. Since the inception of the track, the following metrics have been achieved:
- 18 Companies Supported: The program has successfully shepherded 18 startups through its intensive mentorship and development cycle.
- $120 Million in Capital Raised: Participant companies have demonstrated immense market viability, securing over $120 million in equity funding since joining the program.
- Exits and Acquisitions: Two companies from the alumni cohort have already achieved successful exits, proving the program’s ability to foster companies that provide real value to the medical marketplace.
- $337,000 in Prizes: Beyond private funding, the cohort companies have collectively won over $337,000 in direct prizes through the MTI program, providing essential non-dilutive capital for research and development.
On a global scale, the MedTech Innovator organization—founded in 2013—has supported more than 800 startups. These alumni have collectively secured more than $11 billion in equity funding and have achieved over 500 FDA approvals and authorizations, demonstrating the scale at which this accelerator operates.
Official Perspectives: Bridging the Gap Between Bench and Bedside
The success of the program relies heavily on the synergy between technical innovation and clinical practice. Babak Mehrara, MD, president of The Plastic Surgery Foundation, emphasizes that the primary goal is not just innovation for innovation’s sake, but the purposeful development of patient-centric solutions.
"Plastic surgery has always been a specialty driven by innovation, and the Society’s unique partnership with MedTech Innovator allows us to help shape the next generation of technologies," Dr. Mehrara stated. "By connecting entrepreneurs with the expertise of plastic surgeons, we’re helping ensure these solutions are developed with patients’ needs in mind while accelerating innovations that have the potential to strengthen patient care across the specialty."
The mentorship structure is a cornerstone of this approach. Each startup is paired with a senior industry executive—a "corporate mentor"—who provides individualized guidance on regulatory pathways, reimbursement strategies, and clinical trial design. This high-level coaching is augmented by the input of practicing surgeons, ensuring that when a device or software platform hits the market, it is already optimized for the realities of the operating room.
Implications for the Future of Plastic Surgery
The selection of FeminAI, ImageAssist, GenesisTissue, Tissuelock, and GenAssist signifies a shift in the technological focus of plastic surgery. The inclusion of AI-driven diagnostics and tissue-lock technologies suggests that the future of the specialty lies in precision medicine and enhanced procedural outcomes.
The Role of Plastic Surgery The Meeting
The startups will have a significant platform to demonstrate their progress at Plastic Surgery The Meeting, scheduled for October 15–18 in Houston. This event is not merely a showcase; it is a critical feedback loop. Engaging directly with the surgeon-base allows these startups to refine their user interfaces, troubleshoot potential clinical friction points, and build the professional relationships necessary for long-term adoption.
The Regulatory Landscape
For many startups, the FDA approval process is the primary barrier to entry. Through the MTI program, these five companies receive guidance on navigating the FDA’s complex pathways. As the industry moves toward more sophisticated digital health integration, the regulatory focus has shifted toward data privacy, cybersecurity, and algorithmic transparency—areas where the ASPS can provide specialized guidance to the cohort.
About MedTech Innovator
Based in Los Angeles, MedTech Innovator stands as the world’s largest accelerator for medical technology companies. As a premier nonprofit, its mission is fundamentally aligned with the improvement of patient lives through the advancement of the healthcare system.
The organization operates through a massive network, including 35 corporate partners and over 1,000 industry executives—ranging from venture capitalists and business development leads to regulatory consultants. By providing a platform for constant engagement, the accelerator ensures that startups are not operating in a vacuum. Instead, they are part of a continuous cycle of feedback and strategic support that prepares them to survive and thrive in the competitive global medical market.
Conclusion: A Catalyst for Excellence
The 2026 ASPS and MedTech Innovator cohort represents more than just five promising businesses; it represents a systematic commitment to improving surgical outcomes. By combining the clinical wisdom of the American Society of Plastic Surgeons with the operational expertise of MedTech Innovator, the medical community is ensuring that the tools of tomorrow are built today.
As the industry prepares to gather in Houston this October, the focus will remain on these five companies. Their journey through the accelerator will undoubtedly offer a glimpse into the next decade of plastic and reconstructive surgery, promising a future where technology and human expertise converge to provide safer, more efficient, and more effective care for patients everywhere.
For further information regarding the progress of the cohort and the ongoing partnership, industry stakeholders are encouraged to visit MedTech Innovator’s official website or follow their updates on LinkedIn and X. As these startups refine their technologies, the plastic surgery community stands ready to integrate these innovations, marking another chapter in the specialty’s long history of transformative technological advancement.
About the Author
